June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Pharmacodynamic response of optic nerve head (ONH) tissue blood flow measured by laser speckle flowgraphy (LSFG) after administration of PER-001, an endothelin receptor antagonist
Author Affiliations & Notes
  • Grant Cull
    Discoveries in Sight Laboratories, Devers Eye Institute, Legacy Health, Portland, Oregon, United States
  • Crystal Jadach
    Department of Comparative Medicine, Legacy Research Institute, Legacy Health, Portland, Oregon, United States
  • Juan Reynaud
    Discoveries in Sight Laboratories, Devers Eye Institute, Legacy Health, Portland, Oregon, United States
  • Kristine Ly
    Discoveries in Sight Laboratories, Devers Eye Institute, Legacy Health, Portland, Oregon, United States
  • Michaela Dunn
    Discoveries in Sight Laboratories, Devers Eye Institute, Legacy Health, Portland, Oregon, United States
  • Dawn Jennings
    Discoveries in Sight Laboratories, Devers Eye Institute, Legacy Health, Portland, Oregon, United States
  • Trinity Holthausen
    Discoveries in Sight Laboratories, Devers Eye Institute, Legacy Health, Portland, Oregon, United States
  • Howard Lockwood
    Discoveries in Sight Laboratories, Devers Eye Institute, Legacy Health, Portland, Oregon, United States
  • Stuart Keith Gardiner
    Discoveries in Sight Laboratories, Devers Eye Institute, Legacy Health, Portland, Oregon, United States
  • Lin Wang
    Discoveries in Sight Laboratories, Devers Eye Institute, Legacy Health, Portland, Oregon, United States
  • Jennifer Wilk
    Department of Comparative Medicine, Legacy Research Institute, Legacy Health, Portland, Oregon, United States
  • Brad Fortune
    Discoveries in Sight Laboratories, Devers Eye Institute, Legacy Health, Portland, Oregon, United States
  • Footnotes
    Commercial Relationships   Grant Cull None; Crystal Jadach None; Juan Reynaud None; Kristine Ly None; Michaela Dunn None; Dawn Jennings None; Trinity Holthausen None; Howard Lockwood None; Stuart Gardiner None; Lin Wang None; Jennifer Wilk None; Brad Fortune Perfuse Therapeutics Inc, Code C (Consultant/Contractor), Perfuse Therapeutics Inc, Code F (Financial Support), Heidelberg Engineering, GmbH, Code F (Financial Support)
  • Footnotes
    Support  Perfuse Therapeutics, Inc.; NIH R01-EY030590 (BF); Legacy Good Samaritan Foundation.
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 4029 – A0414. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Grant Cull, Crystal Jadach, Juan Reynaud, Kristine Ly, Michaela Dunn, Dawn Jennings, Trinity Holthausen, Howard Lockwood, Stuart Keith Gardiner, Lin Wang, Jennifer Wilk, Brad Fortune; Pharmacodynamic response of optic nerve head (ONH) tissue blood flow measured by laser speckle flowgraphy (LSFG) after administration of PER-001, an endothelin receptor antagonist. Invest. Ophthalmol. Vis. Sci. 2022;63(7):4029 – A0414.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Reduction of ocular blood flow in glaucoma is thought to be related to upregulation of the endothelin system. Our purpose here was to determine the time course and dose dependency of ONH tissue blood flow in response to a single administration of PER-001.

Methods : LSFG (Softcare Co., Ltd.) was used to measure ONH tissue blood flow (as previously described in detail, PMID: 23737471) in 6 anesthetized adult rhesus monkeys (Macaca mulatta, 4F/2M ages 7-12 y) with unilateral experimental glaucoma (EG). Three LSFG scans were obtained for each eye and averaged at each time point, starting 30 min prior to bilateral intravitreal administration of 50 µL of PER-001 or vehicle, and thereafter every 15-30 min for 6 hr. The dose of PER-001 was varied in random order between 0.001, 0.01, 0.1 mg or vehicle for each subject. The effects of dose, time after administration and eye (EG vs fellow control, FC) were assessed using repeated measures ANOVA, mixed-effects models and generalized estimating equations to include effects of an array of vital signs.

Results : At the beginning of the series of 4 weekly PER-001 assays, ONH neuroretinal minimum rim width in EG and FC eyes, respectively was 155 ± 74 vs 291 ± 39 µm (p=0.005); peripapillary retinal nerve fiber layer thickness was 77 ± 21 vs 100 ± 8.5 µm (p=0.04); and mean blur rate (MBR) from LSFG was 12.3 ± 3.0 vs 14.2 ± 4.9 (p = 0.18); thus, representing a moderate stage of EG damage. Following administration of PER-001 (Figs.1,2), LSFG MBR increased significantly in EG eyes with time after injection (p<0.0001), indicating increased flow; there was a significant time-dose interaction (p<0.0001) and effect of dose (p=0.0006). Whereas, in FC eyes, only the effect of time after injection was significant (p<0.0001). The effect of PER-001 on ONH blood flow was relatively greater in EG eyes such that blood flow increased to a level comparable to FC eyes after ~4 hr, for the mid and high dose. This pattern held after controlling for end-tidal CO2, the only vital sign significantly associated with MBR.

Conclusions : ONH tissue blood flow increased in a dose-dependent manner after administration of PER-001. The effect was more prominent in EG compared to FC eyes, consistent with the hypothesis that upregulation of the endothelin system contributes to reduction of blood flow in glaucoma.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×